Results 161 to 170 of about 16,360 (195)

Blinatumomab bypasses CD28 blockade to sustain T-cell cytotoxicity and improve survival in a xenograft B-ALL model. [PDF]

open access: yesJ Immunother Cancer
Leite GSF   +6 more
europepmc   +1 more source

Vitiligo onset following anti-inflammatory biological therapy: a scoping review. [PDF]

open access: yesFront Immunol
Romagnuolo M   +5 more
europepmc   +1 more source

Abatacept

Nature Reviews Drug Discovery, 2006
Abatacept (Orencia) is the first in a new class of biologics known as selective costimulation modulators. It inhibits full activation of T cells and interacts with other cell types to affect additional mediators of the inflammatory cascade. The clinical efficacy of abatacept in patients with active rheumatoid arthritis, despite prior treatment with ...
Larry Moreland
exaly   +11 more sources

Abatacept in B7-1–Positive Proteinuric Kidney Disease [PDF]

open access: yesNew England Journal of Medicine, 2013
Abatacept (cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion protein [CTLA-4-Ig]) is a costimulatory inhibitor that targets B7-1 (CD80).
Anna Greka, Vineet Gupta, Paolo Fiorina
exaly   +2 more sources

Abatacept

Reactions Weekly, 2016
Abatacept (ABT) is a recombinant fusion protein comprising the extracellular domain of human CTLA4, which inhibits the activation of T cells. Several clinical trials have provided evidence of efficacy and safety of ABT in the patients with rheumatoid athritis (RA) with various clinical characteristics such as MTX inadequate responders (IR), TNF ...
Naoki, Iwamoto, Atsushi, Kawakami
  +6 more sources

Memory B Cells and Response to Abatacept in Rheumatoid Arthritis

open access: yesClinical Reviews in Allergy and Immunology, 2017
International audienceAbatacept is a fusion protein (CTLA4-Ig) and therapeutic molecule labeled for the treatment of rheumatoid arthritis (RA). Abatacept acts both by disrupting the CD28-mediated activation of T cells and by interacting with CD80/CD86 ...
Yves Renaudineau   +2 more
exaly   +4 more sources

Home - About - Disclaimer - Privacy